BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:InventisBio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies InventisBio's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06954961-9088@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taragarestrant: Phase 3 readout est. (NCT06954961)
DESCRIPTION:Taragarestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Adva
 nced or Metastatic Breast Cancer\nEstimated primary completion: 30 Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/taragarestran
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 954961
URL:https://assetmemo.bio/drug/taragarestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326813-62@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07326813)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: A Clinical
  Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of M
 oderate to Severe Plaque Psoriasis\nEstimated primary completion: 12 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nomelcitinib-d-
 2570#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07326813
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130604-62@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07130604)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: Evaluate t
 he Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaqu
 e Psoriasis\nEstimated primary completion: 28 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07130604
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489885-62@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07489885)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Psoriasis.\nStudy: A Study to
  Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis\
 nEstimated primary completion: August 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07489885
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315061-62@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07315061)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2.\nStudy: A Phase II Study to Ev
 aluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic
  Arthritis\nEstimated primary completion: 15 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07315061
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625891-62@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07625891)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Vitiligo.\nStudy: Study of D-
 2570 in Subjects With Non-Segmental Vitiligo\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nome
 lcitinib-d-2570#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07625891
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379946-2488@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anfangning (Garsorasib): Phase 1/2 readout est. (NCT05379946)
DESCRIPTION:Anfangning (Garsorasib)\, phase 1/2.\nStudy: Study to Evaluate 
 D-1553 in Combination With IN10018 in Subjects With Solid Tumors\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/garsorasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05379946
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041776-2235@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Befotertinib: Phase 3 readout est. (NCT06041776)
DESCRIPTION:Befotertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 juvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Posit
 ive EGFR Sensitive Mutations\nEstimated primary completion: 30 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/befotertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06041776
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311200-62@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07311200)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Systemic Lupus Erythematosus.
 \nStudy: A Study of D-2570 in Patients With Active Systemic Lupus Erythema
 tosus (SLE)\nEstimated primary completion: 31 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07311200
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181499-2235@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07181499)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Se
 quential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSC
 LC) Patients With Resistance to Third-Generation EGFR-TKI\nEstimated prima
 ry completion: November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/befotertinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07181499
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
